Cargando…
Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 m...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646574/ https://www.ncbi.nlm.nih.gov/pubmed/34695227 http://dx.doi.org/10.1002/eji.202149619 |
_version_ | 1784610499427565568 |
---|---|
author | Canto e Castro, Luísa Gomes, Andreia Serrano, Marta Pereira, Ana Helena Guia Ribeiro, Rita Napoleão, Patrícia Domingues, Inês Silva, Cláudia Fanczal, Júlia Afonso, Ângela Lopes, Andreia Toader, Ionela de Sousa, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano Mota, Maria M. Silva‐Santos, Bruno Veldhoen, Marc Ribeiro, Ruy M. |
author_facet | Canto e Castro, Luísa Gomes, Andreia Serrano, Marta Pereira, Ana Helena Guia Ribeiro, Rita Napoleão, Patrícia Domingues, Inês Silva, Cláudia Fanczal, Júlia Afonso, Ângela Lopes, Andreia Toader, Ionela de Sousa, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano Mota, Maria M. Silva‐Santos, Bruno Veldhoen, Marc Ribeiro, Ruy M. |
author_sort | Canto e Castro, Luísa |
collection | PubMed |
description | During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long‐lasting infection immunity against SARS‐CoV‐2. Moreover, vaccinated people had higher IgG levels from 3 weeks post‐vaccination when compared with previously infected people at the same time post‐infection. |
format | Online Article Text |
id | pubmed-8646574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86465742021-12-06 Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection Canto e Castro, Luísa Gomes, Andreia Serrano, Marta Pereira, Ana Helena Guia Ribeiro, Rita Napoleão, Patrícia Domingues, Inês Silva, Cláudia Fanczal, Júlia Afonso, Ângela Lopes, Andreia Toader, Ionela de Sousa, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano Mota, Maria M. Silva‐Santos, Bruno Veldhoen, Marc Ribeiro, Ruy M. Eur J Immunol Immunity to infection During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long‐lasting infection immunity against SARS‐CoV‐2. Moreover, vaccinated people had higher IgG levels from 3 weeks post‐vaccination when compared with previously infected people at the same time post‐infection. John Wiley and Sons Inc. 2021-11-10 2022-01 /pmc/articles/PMC8646574/ /pubmed/34695227 http://dx.doi.org/10.1002/eji.202149619 Text en © 2021 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Immunity to infection Canto e Castro, Luísa Gomes, Andreia Serrano, Marta Pereira, Ana Helena Guia Ribeiro, Rita Napoleão, Patrícia Domingues, Inês Silva, Cláudia Fanczal, Júlia Afonso, Ângela Lopes, Andreia Toader, Ionela de Sousa, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano Mota, Maria M. Silva‐Santos, Bruno Veldhoen, Marc Ribeiro, Ruy M. Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title | Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title_full | Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title_fullStr | Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title_full_unstemmed | Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title_short | Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection |
title_sort | longitudinal sars‐cov‐2 seroprevalence in portugal and antibody maintenance 12 months after infection |
topic | Immunity to infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646574/ https://www.ncbi.nlm.nih.gov/pubmed/34695227 http://dx.doi.org/10.1002/eji.202149619 |
work_keys_str_mv | AT cantoecastroluisa longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT gomesandreia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT serranomarta longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT pereiraanahelenaguia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT ribeirorita longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT napoleaopatricia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT dominguesines longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT silvaclaudia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT fanczaljulia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT afonsoangela longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT lopesandreia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT toaderionela longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT desousamariajoserego longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT desousajosegermanorego longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT desousagermano longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT motamariam longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT silvasantosbruno longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT veldhoenmarc longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection AT ribeiroruym longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection |